Chargement en cours...
Economic impact of new active substance status on EU payers’ budgets: example of dimethyl fumarate (Tecfidera(®)) for multiple sclerosis
BACKGROUND: Recently, collaboration between regulators and payers was set up and was mainly focused on evidence generation along product clinical development. However, neither the regulatory path nor the new active substance status (NASs) was considered. Granting NASs will provide the product with 8...
Enregistré dans:
| Publié dans: | J Mark Access Health Policy |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Co-Action Publishing
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4865780/ https://ncbi.nlm.nih.gov/pubmed/27226838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3402/jmahp.v2.23932 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|